These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29461823)

  • 1. Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.
    Thompson AM; O'Connor PD; Marshall AJ; Blaser A; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Wan B; Franzblau SG; Ma Z; Cooper CB; Denny WA
    J Med Chem; 2018 Mar; 61(6):2329-2352. PubMed ID: 29461823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.
    Thompson AM; O'Connor PD; Marshall AJ; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Franzblau SG; Wan B; Wang Y; Ma Z; Cooper CB; Denny WA
    J Med Chem; 2017 May; 60(10):4212-4233. PubMed ID: 28459575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.
    Thompson AM; O'Connor PD; Blaser A; Yardley V; Maes L; Gupta S; Launay D; Martin D; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
    J Med Chem; 2016 Mar; 59(6):2530-50. PubMed ID: 26901446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
    Thompson AM; O'Connor PD; Marshall AJ; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Wan B; Franzblau SG; Ma Z; Cooper CB; Denny WA
    Eur J Med Chem; 2021 Jan; 209():112914. PubMed ID: 33268145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
    Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
    J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity.
    Mowbray CE; Braillard S; Speed W; Glossop PA; Whitlock GA; Gibson KR; Mills JE; Brown AD; Gardner JM; Cao Y; Hua W; Morgans GL; Feijens PB; Matheeussen A; Maes LJ
    J Med Chem; 2015 Dec; 58(24):9615-24. PubMed ID: 26571076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a new class of natural product-inspired quinazolinone hybrid as potent antileishmanial agents.
    Sharma M; Chauhan K; Shivahare R; Vishwakarma P; Suthar MK; Sharma A; Gupta S; Saxena JK; Lal J; Chandra P; Kumar B; Chauhan PM
    J Med Chem; 2013 Jun; 56(11):4374-92. PubMed ID: 23611626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Palmer BD; Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA; Thompson AM
    J Med Chem; 2015 Apr; 58(7):3036-59. PubMed ID: 25781074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
    Eberhardt E; Mondelaers A; Hendrickx S; Van den Kerkhof M; Maes L; Caljon G
    Parasitol Res; 2016 Oct; 115(10):4061-70. PubMed ID: 27412759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of leishmaniasis. Part XII: design, synthesis and bioevaluation of novel triazole integrated phenyl heteroterpenoids as antileishmanial agents.
    Suryawanshi SN; Tiwari A; Kumar S; Shivahare R; Mittal M; Kant P; Gupta S
    Bioorg Med Chem Lett; 2013 May; 23(10):2925-8. PubMed ID: 23582274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.
    Kaur J; Sundar S; Singh N
    J Antimicrob Chemother; 2010 Aug; 65(8):1742-8. PubMed ID: 20519355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
    Kmentova I; Sutherland HS; Palmer BD; Blaser A; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA; Thompson AM
    J Med Chem; 2010 Dec; 53(23):8421-39. PubMed ID: 21069962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antileishmanial activity of benzocycloalkyl azole oximino ethers: the conformationally constraint analogues of oxiconazole.
    Verma A; Srivastava S; Sane SA; Marrapu VK; Srinivas N; Yadav M; Bhandari K; Gupta S
    Acta Trop; 2011 Feb; 117(2):157-60. PubMed ID: 21078278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of allicin on promastigotes and intracellular amastigotes of Leishmania donovani and L. infantum.
    Jesús Corral-Caridad M; Moreno I; Toraño A; Domínguez M; Alunda JM
    Exp Parasitol; 2012 Dec; 132(4):475-82. PubMed ID: 22995646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis.
    Mukkavilli R; Pinjari J; Patel B; Sengottuvelan S; Mondal S; Gadekar A; Verma M; Patel J; Pothuri L; Chandrashekar G; Koiram P; Harisudhan T; Moinuddin A; Launay D; Vachharajani N; Ramanathan V; Martin D
    Eur J Pharm Sci; 2014 Dec; 65():147-55. PubMed ID: 25261338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antileishmanial activity and modification of hepatic xenobiotic metabolizing enzymes in golden hamster by 2(3)-tert-butyl-4-hydroxyanisole following infection with Leishmania donovani.
    Mukhopadhyay R; Madhubala R
    Biochem Pharmacol; 1994 Jan; 47(2):253-6. PubMed ID: 8304969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi.
    Oh S; Kim S; Kong S; Yang G; Lee N; Han D; Goo J; Siqueira-Neto JL; Freitas-Junior LH; Song R
    Eur J Med Chem; 2014 Sep; 84():395-403. PubMed ID: 25036797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of antileishmanial activity of trans-aconitic acid.
    Misra S; Sanyal T; Sarkar D; Bhattacharya PK; Ghosh DK
    Biochem Med Metab Biol; 1989 Dec; 42(3):171-8. PubMed ID: 2597432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of chalcones as potential antileishmanial agents.
    Gupta S; Shivahare R; Korthikunta V; Singh R; Gupta S; Tadigoppula N
    Eur J Med Chem; 2014 Jun; 81():359-66. PubMed ID: 24858541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
    Gopinath VS; Pinjari J; Dere RT; Verma A; Vishwakarma P; Shivahare R; Moger M; Kumar Goud PS; Ramanathan V; Bose P; Rao MV; Gupta S; Puri SK; Launay D; Martin D
    Eur J Med Chem; 2013 Nov; 69():527-36. PubMed ID: 24095747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.